Navigation Links
Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
Date:8/4/2009

PALO ALTO, Calif., August 4, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that it has licensed the exclusive worldwide rights to novel Hepatitis C Virus (HCV) technology from Stanford University. This technology, discovered in the lab of Stanford scientist and Eiger founder Dr. Jeffrey Glenn, M.D., Ph.D., is focused on a variety of novel targets, including key features of NS4B, a non-structural protein in the HCV genome, which binds to HCV-RNA and is required for viral replication.

"We are delighted to have licensed the rights to this exciting new technology from Stanford University," said David Cory, President and CEO of Eiger. "Disrupting the interaction between NS4B and HCV-RNA may be a promising new method to treat HCV infection and help combat drug resistance to HCV polymerase and protease inhibitors. We are rapidly advancing novel small molecule inhibitors of NS4B-RNA binding into the clinic for the benefit of clinicians and HCV patients."

"The unique two component nature of the NS4B-RNA target appears to decrease the virus' ability to escape inhibition by the small molecule inhibitors in development at Eiger, and that should decrease HCV resistance to this type of antiviral therapy," said Jeffrey Glenn. "These virus specific agents in development at Eiger possess the promise of more effective, oral drugs that can be essential components of all future cocktails for HCV therapy."

About Hepatitis C Virus

Infections from HCV have reached pandemic proportions, affecting over 150 million people worldwide. According to the Centers for Disease Control (CDC), 3.9 million Americans have been exposed to HCV, resulting in 2.7 million cases of chronic infection. Chronic HCV infection leads to serious liver disease (e.g. liver scarring and cirrhosis) and is the leading cause of liver cancer
'/>"/>

SOURCE Eiger BioPharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Eiger BioPharmaceuticals Raises $7.1 Million A Round
2. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
3. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
5. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
6. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
7. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
9. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
10. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
11. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 Earlier this year ... L. Sherley, director of the Adult Stem Cell Technology ... often overlooked and under appreciated unique property of adult ... Distributed Stem Cells: Misunderstood in the Past, Important for ... congress participants. He gave the address at the ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application ... product specification, manufacturing process, and product cost ... and applications. The analysis also covers upstream ... channels, industry development trend and proposals. In ...
(Date:12/24/2014)... 23, 2014 China Biologic Products, Inc. ... leading fully integrated plasma-based biopharmaceutical company in ... majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., ... the China Food and Drug Administration (the "CFDA") ... previously disclosed in the Company,s public filings, the ...
(Date:12/24/2014)... 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... a Clinical Trial Application (CTA) with the ... (MHRA) seeking regulatory approval to initiate clinical trials for ... Contingent on the Company receiving CTA regulatory ... trial to assess the safety, tolerability and dose escalation ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... JOSE, Calif., March 12 Oncolys BioPharma,Inc. (Tokyo, ... USA),announced today that they have entered into a ... throughout Asia, Tacere,s,RNA interference (RNAi)-based Hepatitis C virus ... agreement resulted from the,strategic alliance entered into by ...
... HAS CLINCIAL, CORPORATE AND REGULATORY EXPERIENCE IN STEM ... ... Corp. (Nasdaq: KOOL ), a leading supplier of innovative,products that ... Vice President, Stem Cells and Regenerative Medicine at,Invitrogen Corporation, has been ...
... 12 f-star, an antibody,engineering company developing novel ... Antibody Technology, announced today that it,will open a ... its,headquarters in Vienna, Austria. The facility will be ... number of biotech companies and close,to the Medical ...
Cached Biology Technology:Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 2Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 3ThermoGenesis Names Dr. Mahendra Rao to Board of Directors 2ThermoGenesis Names Dr. Mahendra Rao to Board of Directors 3ThermoGenesis Names Dr. Mahendra Rao to Board of Directors 4Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK 2
(Date:12/22/2014)... 2014  The 2014 Holiday Season may be ... Acuity Market Intelligence reports that the long anticipated ... Acuity forecasts that intensifying demand for smart phones, ... will drive a global market of 2.5 billion ... 2020.   According to Maxine ...
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... Scientists have decoded the genome of a bacterium that is threatening ... an iconic sight in Britain since its introduction in the 1500s ... over 70 per cent of trees in some areas. Bleeding canker, ... Pae ), causes lesions which bleed like open sores and in ...
... questions about climate change, a new book by Claire ... Space Flight Center in Greenbelt, Md., can provide some ... the Past, Beware the Big Fix," will be published ... why global warming is such a big deal, summarizes ...
... April 19, 2010 Not all animals crave green spaces. ... and this particularity will be addressed by Danielle Dagenais, a ... as part of the Sommet sur la biodiversit et le ... of the most interesting case studies is the Black Redstart. ...
Cached Biology News:Conquering conker canker 2NASA scientist publishes new book: 'Coming Climate Crisis? Consider the Past, Beware the Big Fix' 2Urban wildlife: Some birds crave cement, not trees 2
Kit includes your choice of reagents for labeling 3 x 10 9 cells and EasySep magnet....
... stabilizing 1.5mg of purified RNA samples., , ... stabilization of aqueous RNA samples that have ... guanidine, phenol/chloroform, silica, oligo dT etc or ... all the necessary components for the stabilization ...
Blasticidin resistance gene (bsr), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Plasmid expressing Zeocin resistance gene....
Biology Products: